Cytori Receives Key Cell Therapy Patent for Scleroderma
July 06 2017 - 7:00AM
Strengthens Global Scleroderma
Intellectual Property Portfolio
Cytori Therapeutics, Inc. (NASDAQ:CYTX) (“Cytori” or the
“Company”) announced today the issuance of key patents that
strengthen its intellectual property portfolio in the U.S. and
Europe. Cytori now has 107 global patents issued and another 45
patent applications pending around the globe. Several of Cytori’s
recently issued patents contain claims covering the use of Habeo™
Cell Therapy for patients with scleroderma affecting the hands.
- On July 5, 2017 the European Patent Office (EPO) issued Patent
No. 3046417, which claims the use of Adipose-Derived Regenerative
Cells (ADRCs), including Cytori’s Habeo™ Cell Therapy for
scleroderma, including treatment of Raynaud’s Phenomenon or
suppression of pain from Raynaud’s Phenomenon. This patent
has a term at least through 2034.
- On April 19, 2017, the EPO issued Patent No. 1670315, which
claims the use of ADRCs, including Cytori’s Habeo™ Cell Therapy, to
treat vascular diseases, which are disorders that affect the blood
carrying vessels of the body. Vascular disease is a very common
complication in patients with scleroderma where it can contribute
to digital ulcers and other problems. This patent has a term at
least through 2024 and covers the use of Habeo™ Cell Therapy for
vascular diseases, including but not limited to disease associated
with scleroderma.
- On December 6, 2016, the U.S. Patent Office issued Patent No.
9511096, which claims the use of ADRCs, including Cytori Cell
Therapy™, to treat ischemic wounds. This patent has a term at least
through December 2022 and covers the use of Habeo™ Cell Therapy for
treatment of digital ulcers in scleroderma patients.
"Building on Cytori’s broad intellectual property portfolio
continues to be a priority," said John D. Harris, Vice President
and General Manager, Cell Therapy. "Our intellectual property
strategy is to continue to strengthen the Cytori Cell Therapy™
platform to help establish and maintain a sustainable
competitive advantage. Our main focus is on the primary therapeutic
targets of scleroderma and Raynaud’s Phenomenon, though we will
continue to seek additional intellectual property in other
therapeutic areas as well."
About Cytori
Cytori is a therapeutics company developing regenerative and
oncologic therapies from its proprietary cell therapy and
nanoparticle platforms for a variety of medical conditions. Data
from preclinical studies and clinical trials suggest that Cytori
Cell Therapy™ acts principally by improving blood flow, modulating
the immune system, and facilitating wound repair. As a result,
Cytori Cell Therapy™ may provide benefits across multiple disease
states and can be made available to the physician and patient at
the pointofcare through Cytori’s proprietary technologies and
products. Cytori Nanomedicine™ is developing liposome encapsulated
therapies for regenerative medicine and oncologic indications. For
more information, please visit www.cytori.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release includes forward-looking statements that
involve known and unknown risks and uncertainties. All statements,
other than historical facts are forward looking statements. Such
statements, including statements regarding projected patent terms,
Cytori’s patent strategy and areas of interest, and potential uses
of Cytori’s patent portfolio to support its product pipeline, are
subject to risks and uncertainties that could cause our actual
results and financial position to differ materially. Some of these
risks include risks related to protection and enforcement of our
intellectual property portfolio such as risks regarding infringing
or competing third party intellectual property, risks that our
intellectual property may infringe other intellectual property
rights (or may be at risk of challenge or invalidation), or risks
that the claims in our patents and patent applications may not be
granted, may be successfully challenged ,or may be insufficient in
coverage or scope to support and achieve our corporate objectives,
and other risks and uncertainties described under the "Risk
Factors" in Cytori’s Securities and Exchange Commission Filings,
included in our annual and quarterly reports.
There may be events in the future that we are unable to predict,
or over which we have no control, and our business, financial
condition, results of operations and prospects may change in the
future. We assume no responsibility to update or revise any
forward-looking statements to reflect events, trends or
circumstances after the date they are made unless we have an
obligation under U.S. Federal securities.
Cytori Therapeutics, Inc.
Tiago Girao, 1-858-458-0900
ir@cytori.com
Cytori Therapeutics (NASDAQ:CYTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cytori Therapeutics (NASDAQ:CYTX)
Historical Stock Chart
From Apr 2023 to Apr 2024